New York lawmaker proposes e-cigarette prevention program in schools

Aug.01.2022
New York lawmaker introduces bill to require e-cigarette prevention programs in schools to combat teenage vaping.

Keith Brown, a D-Northport legislator, has introduced A.10547 to amend the state's public health law. The bill would require those who use electronic cigarettes or vaping products in schools to participate in electronic cigarette or vaping prevention, control, or awareness programs. This program would be part of a larger statewide effort in New York to create an education initiative for schools aimed at preventing electronic cigarette use. According to the bill text, children under the age of 21 found to be using or in possession of electronic cigarettes or vaping products would also be notified to their parents or guardians.


E-cigarettes are a relatively new product that has been marketed towards non-smoking young people with a variety of sweet-flavored e-liquids and advertising campaigns," Brown wrote in his legislative reasoning. "In addition, certain e-cigarettes designed for young people are small, stylish and can be easily hidden by authorities, with user-friendly pre-filled liquid pods that contain as much nicotine as a pack of cigarettes. The New York State Department of Health has received numerous reports from doctors across New York state of patients aged between 14 and 71 who had used an e-cigarette product before becoming ill.


As Brown's legislation is being introduced, the federal government is considering a review of Juul, one of the largest electronic cigarette manufacturers. On June 23, the FDA ordered Juul to withdraw its products from the market. A day later, the Federal Appeals Court temporarily blocked the government's ban at Juul's request. The FDA then decided to suspend the court proceedings while the government resumed its review of Juul's products.


According to documents, if the FDA ultimately decides to reinstate the ban, Juul will have 30 days to seek another stay. As reported by the Associated Press, the company must prove that its e-cigarettes are beneficial to public health in order to remain on the market. In practice, this means demonstrating that adult smokers who use them may quit or cut back on smoking, while adolescents are unlikely to become addicted to them.


According to a report by the Associated Press, the FDA regulatory agency recently authorized electronic cigarettes from major competitors of Juul, including RJ Reynolds and NJOY. However, industry stakeholders and anti-vaping advocates have been eagerly waiting for the FDA's decision on Juul products, which are the top-selling e-cigarettes in the United States. The FDA initially stated that Juul's application left significant issues with the regulatory agency, including concerns about the chemicals in the e-liquid. Juul has stated that it has submitted enough information and data to address all the raised concerns.


Meanwhile, the European Commission has announced that its proposal is to address the significant increase in sales of such products in 27 countries/regions. According to reports from the Associated Press, a recent commission study showed that sales of heated tobacco products increased by 10% in five or more member states, while these products accounted for over 2.5% of total tobacco product sales in the region. The ban will cover devices that use heated tobacco to produce emissions containing nicotine for inhalation by users. Electronic cigarettes may contain nicotine, but not tobacco. When using traditional cigarettes, users inhale smoke generated by burning tobacco.


The results of FDA's review of Juul and the proposed ban by the European Commission could affect the appeal of Brown's legislation in state legislatures when the legislative session begins next year. Brown's bill takes a tough stance on the practicality of e-cigarettes.


Young people using e-cigarettes is a major public health issue, as they are using them more frequently than traditional tobacco products such as cigarettes, cigars, smokeless tobacco, and hookahs,” wrote Brown in his legislative rationale. “In fact, the number of high school students using e-cigarettes in New York State is almost five times the number smoking cigarettes, and while the youth smoking rate in New York State is at an all-time low (4.3%), their e-cigarette usage rates have increased from 10.5% to 20.6% between 2014 and 2016. Although few high school students say they plan to try smoking, more and more are willing to try e-cigarettes. More than half of teenagers think e-cigarettes cause little or some harm not used every day, and among young e-cigarette users, a third mistakenly believe that non-daily e-cigarette use is harmless. Using e-cigarettes does not prevent smoking; in fact, the risk of starting or continuing smoking increases among young people who use e-cigarettes, with more than half of high school and young adult cigarette smokers also using e-cigarettes.


This article contains excerpts or reprints from third-party sources, and the copyright belongs to the original media and author. If there is any infringement, please contact us for deletion. Any organization or individual who needs to reproduce it, please contact the author, and do not reproduce it directly.



Disclaimer

This article is provided solely for professional research, industry discussion, and informational purposes. Any references to brands, companies, products, technologies, or policies are made for factual reporting and analytical purposes only, and do not constitute endorsement, recommendation, promotion, or advertising by 2Firsts.

Nicotine-containing products, including but not limited to cigarettes, e-cigarettes, heated tobacco products, and nicotine pouches, carry significant health risks. Readers are responsible for complying with all applicable laws and regulations in their respective jurisdictions, including age restrictions and access limitations.

The information contained in this article should not be regarded as investment, legal, medical, regulatory, or commercial advice. While 2Firsts strives to ensure the accuracy and reliability of its content, it does not assume liability for any direct or indirect loss arising from errors, omissions, inaccuracies, or reliance on the information contained herein.

This article is not intended for individuals below the legal age for accessing tobacco or nicotine-related information in their jurisdiction.

 

Copyright Notice

This article is either original content produced by 2Firsts or content reproduced, translated, summarized, or adapted from third-party sources with attribution where applicable. The intellectual property rights of the original content remain with 2Firsts or the respective original rights holders.

No individual or organization may copy, reproduce, distribute, republish, modify, translate, or otherwise use this content without prior authorization. Any unauthorized use may result in legal action.

For copyright-related inquiries, corrections, or removal requests, please contact: info@2firsts.com.

 

AI-Assisted Translation and Editing Notice

Portions of this article may have been translated, edited, or reviewed with the assistance of artificial intelligence tools to improve efficiency and readability. Due to the limitations of AI-assisted translation and editing, discrepancies, omissions, or inaccuracies may exist when compared with the original source.

Where applicable, readers are advised to refer to the original source for the most complete and accurate information. If you identify any errors or believe that any content infringes upon your rights, please contact us at info@2firsts.com, and we will review and address the matter promptly.

PMI Expands U.S. ZYN Portfolio With New 1.5 mg and 8 mg Strengths, Moves Toward a Unified 20-Pouch-Per-Can Format
PMI Expands U.S. ZYN Portfolio With New 1.5 mg and 8 mg Strengths, Moves Toward a Unified 20-Pouch-Per-Can Format
Philip Morris International is expanding its U.S. ZYN nicotine pouch portfolio with new 1.5 mg and 8 mg strengths and plans to move its core 3 mg and 6 mg dry-pouch products from 15 to 20 pouches per can in the fourth quarter of 2026. ZYN ULTRA is also commercially available, with FDA authorization covering 10 products at 9 mg and one 11 mg Smooth product. PMI U.S. lists the new 1.5 mg and 8 mg strengths as commercially available, but as of September 10 they do not appear on the FDA’s public authorization list. Public materials do not identify which PMTA submissions cover the two new strengths or their current review status.
Sep.11
Reynolds Showcases Vuse Pro Flavors and VELO Nicotine Pouches at NACS Show 2026
Reynolds Showcases Vuse Pro Flavors and VELO Nicotine Pouches at NACS Show 2026
Reynolds American, a BAT subsidiary, showcased four Vuse Pro flavored e-cigarette pods and its VELO nicotine pouch portfolio at NACS Show 2026. Booth staff confirmed to 2Firsts that the Vuse Pro flavors are sold in the U.S., although they have not received FDA marketing authorization. BAT outlined plans to expand Vuse retail distribution and reported that VELO held a 30.5% year-to-date volume share of the U.S. modern oral nicotine category through August 2026. The booth also featured the newly launched VELO MAX range and merchandising displays combining cigarettes, vaping products and oral nicotine brands.
EXPO
Oct.09
Wall Street Journal: U.S. FDA Plans Faster Vape and Nicotine Pouch Reviews, Revisit of 2021 PMTA Rule
Wall Street Journal: U.S. FDA Plans Faster Vape and Nicotine Pouch Reviews, Revisit of 2021 PMTA Rule
The Trump administration is preparing changes intended to accelerate FDA market authorization reviews for e-cigarettes and nicotine pouches, according to The Wall Street Journal. The FDA is expected to revisit its 2021 PMTA rule and may simplify some scientific study requirements and shorten review times. The agency has not formally announced the changes. Over the past year, the FDA has already accelerated nicotine-pouch reviews, expanded ENDS authorizations and upgraded its CTP Portal NextGen application system. As of August 2026, 43 nicotine pouch products and 48 e-cigarette products had received FDA marketing authorization.
Sep.24
Product | JTI Introduces Fully Dissolvable PERLZ Nicotine Pearls in UK, Expands Range From 30-Pearl Dispensers to 10-Pearl Sachets
Product | JTI Introduces Fully Dissolvable PERLZ Nicotine Pearls in UK, Expands Range From 30-Pearl Dispensers to 10-Pearl Sachets
Japan Tobacco International (JTI) has introduced PERLZ nicotine pearls in the UK, expanding its oral nicotine portfolio beyond conventional nicotine pouches. The fully dissolvable, multi-layer pearls are placed under the tongue and come in Mint and Berry flavors at concentrations of 1mg/g and 2mg/g, equivalent to approximately 0.3mg and 0.5mg of nicotine per pearl. UK retailer Haypp published four 30-pearl dispenser listings on July 31, 2026, followed by three 10-pearl sachet products on August 17. The dispensers retail for £6.50, while the sachets cost £2.50.
product
Oct.12
Australia Brings in Deloitte to Support Illicit Tobacco and Vape Enforcement Across Data, Processes and Project Delivery
Australia Brings in Deloitte to Support Illicit Tobacco and Vape Enforcement Across Data, Processes and Project Delivery
Australia’s Department of Home Affairs has hired Deloitte to provide data analytics, business-process, communications and project-delivery support to the Office of the Illicit Tobacco and E-Cigarette Commissioner. The government says Deloitte personnel do not provide policy advice to the Commissioner or the Australian government, with policy development and decision-making remaining with public officials. The arrangement has nevertheless drawn scrutiny because Deloitte has previously provided professional services to several tobacco and vaping companies.
Sep.03
Canada Considers Easing Pharmacy-Only Nicotine Pouch Sales Rules, Potentially Reopening Convenience Store Channel
Canada Considers Easing Pharmacy-Only Nicotine Pouch Sales Rules, Potentially Reopening Convenience Store Channel
Canada's federal government is considering changes to current restrictions on where nicotine pouches can be sold, potentially allowing authorized products to return to convenience stores and other general retail channels, although no decision has been made. Since 2024, emerging nicotine replacement therapy products such as nicotine pouches have been largely restricted to behind-the-counter pharmacy sales. Health Canada, meanwhile, continues to recall unauthorized and higher-strength nicotine pouches, indicating that the current discussion concerns retail access for authorized products rather than a broad relaxation of nicotine pouch regulation.
Sep.14